Camrelizumab Biosimilar, Anti-human PD-1 Monoclonal Antibody

Catalog No.	C028P
Product Name	Camrelizumab Biosimilar, Anti-human PD-1 Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	programmed cell death protein 1, PD1, CD279, cluster of differentiation 279
Summary	Recombinant Humanized IgG4-k Monoclonal Antibody.
Source/Host	The anti-human PD-1 monoclonal antibody camrelizumab biosimilar was produced in the camrelizumab biosimilar CHO stable cell line.
Specificity/Sensitivity	The in vivo grade camrelizumab biosimilar specifically binds to the programmed cell death protein 1 (PD1), antagonizing its interaction with its known ligands PD-L1 and PD-L2.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by camrelizumab.
Form Of Antibody	0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade camrelizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Camrelizumab biosimilar protein is for research use only (RUO). Recombinant human IgG4 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C028P: Camrelizumab Biosimilar, Anti-human PD-1 Monoclonal Antibody

Recombinant Humanized IgG4-k Monoclonal Antibody.

Background

Camrelizumab Biosimilar uses the same protein sequences as the therapeutic antibody camrelizumab.

Camrelizumab is an IgG4κ humanized monoclonal antibody being investigated for hepatocellular carcinoma. It targets programmed cell death protein 1 (PD-1), a protein on the surface of cells, also known as CD279 (cluster of differentiation 279). Camrelizumab is being evaluated in the Phase 2/3 (NCT02989922) of patients with advanced hepatocellular carcinoma (HCC) in second-line after failure or intolerance to prior systemic treatment. The study has 2 arms in which patients will be intravenous administered 3 mg/kg SHR-1210 on day 1 every 2 weeks or every 3 weeks. The primary outcome measures are the overall response rate (ORR) and overall survival (OS) rates at 6 months with duration of response and OS at 2 years as secondary endpoints. The estimated enrollment is 220 patients, and the estimated primary completion date is December 2018. A randomized, open-label Phase 3 study (NCT03099382) is evaluating the efficacy of camrelizumab treatment compared to standard-of-care treatment (docetaxel or irinotecan) in patients with esophageal carcinoma. Patients are randomly assigned to receive either SHR-1210 (200 mg every 2 weeks) or the standard of care (docetaxel 75 mg/m2 on day 1 every 3 weeks or irinotecan 180 mg/m2 on day 1 every 2 weeks). This Phase 3 study has an estimated enrollment of 438 and an estimated primary completion date of June 2018.

Syd Labs provides the following research grade anti-PD-L1 / PD-1 antibody biosimilar proteins:
Atezolizumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Avelumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Camrelizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Cemiplimab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Durvalumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Nivolumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Pembrolizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Spartalizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody

PD-1 is a member of the extended CD28/CTLA-4 family of T cell regulators. Syd Labs provides the following research grade anti-CTLA-4 antibody biosimilars:
Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody

Syd Labs provides the following anti-mouse PD-L1 / PD-1 antibodies:
In vivo grade recombinant anti-mouse PD1 monoclonal antibodies (Clone 29F.1A12.1)
In vivo grade recombinant anti-mouse PD-1 monoclonal antibodies (Clone RMP1-14.1)
In vivo grade recombinant anti-mouse PD-L1 monoclonal antibodies (Clone 10F.9G2.1)

Please remember our product information: Camrelizumab Biosimilar, PD-1 Monoclonal Antibody: C028P Syd Labs

Additional information

Size	1 mg, 20 mg, 5 mg

No more offers for this product!